BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: American Association for the Study of Liver Diseases. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014;61:642-659. [PMID: 25015420 DOI: 10.1016/j.jhep.2014.05.042] [Cited by in Crossref: 212] [Cited by in F6Publishing: 164] [Article Influence: 26.5] [Reference Citation Analysis]
Number Citing Articles
1 Snehavardhan P, Lal BB, Sood V, Khanna R, Alam S. Efficacy and Safety of Sodium Benzoate in The Management of Hyperammonemia in Decompensated Chronic Liver Disease of the Childhood—A Double-blind Randomized Controlled Trial. Journal of Pediatric Gastroenterology & Nutrition 2020;70:165-70. [DOI: 10.1097/mpg.0000000000002521] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Greinert R, Zipprich A, Simón-Talero M, Stangl F, Ludwig C, Wienke A, Praktiknjo M, Höhne K, Trebicka J, Genescà J, Ripoll C. Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. Liver Int 2020;40:3093-102. [PMID: 32890428 DOI: 10.1111/liv.14660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Swaminathan M, Ellul MA, Cross TJ. Hepatic encephalopathy: current challenges and future prospects. Hepat Med. 2018;10:1-11. [PMID: 29606895 DOI: 10.2147/hmer.s118964] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
4 Bittencourt PL, Terra C, Parise ER, Farias AQ, Arroyo V, Fernandez J, Pereira G, Maubouisson LM, Andrade GM, Costa FG, Codes L, Andrade AR, Mattos AA, Torres A, Couto F, Zyngier I. Intensive care management of patients with liver disease: proceedings of a single-topic conference sponsored by the Brazilian Society of Hepatology. Arq Gastroenterol 2015;52 Suppl 1:55-72. [PMID: 26959806 DOI: 10.1590/S0004-28032015000500004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fuhrmann V, Whitehouse T, Wendon J. The ten tips to manage critically ill patients with acute-on-chronic liver failure. Intensive Care Med 2018;44:1932-5. [DOI: 10.1007/s00134-018-5078-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mayer LB, Krawczyk M, Grünhage F, Lammert F, Stokes CS. A genetic variant in the promoter of phosphate-activated glutaminase is associated with hepatic encephalopathy. J Intern Med 2015;278:313-22. [DOI: 10.1111/joim.12374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Jeong JY, Jun DW, Bai D, Kim JY, Sohn JH, Ahn SB, Kim SG, Kim TY, Kim HS, Jeong SW, Cho YK, Song DS, Kim HY, Jung YK, Yoon EL. Validation of a Paper and Pencil Test Battery for the Diagnosis of Minimal Hepatic Encephalopathy in Korea. J Korean Med Sci. 2017;32:1484-1490. [PMID: 28776344 DOI: 10.3346/jkms.2017.32.9.1484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72:320-341. [PMID: 31954495 DOI: 10.1016/j.jhep.2019.10.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 40.0] [Reference Citation Analysis]
9 Xu XY, Ding HG, Li WG, Jia JD, Wei L, Duan ZP, Liu YL, Ling-Hu EQ, Zhuang H, Hepatology CSO, Association CM. Chinese guidelines on management of hepatic encephalopathy in cirrhosis. World J Gastroenterol 2019; 25(36): 5403-5422 [PMID: 31576089 DOI: 10.3748/wjg.v25.i36.5403] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
10 Lv Y, Li K, He C, Luo B, Zhang B, Liu H, Wang Z, Guo W, Wang Q, Chen H, Bai W, Yuan X, Yu T, Li X, Yuan J, Han N, Zhu Y, Niu J, Xie H, Wang J, Chen L, Yin Z, Fan D, Li Z, Han G. TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis. Aliment Pharmacol Ther. 2019;49:926-939. [PMID: 30820990 DOI: 10.1111/apt.15186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, Ebadi M, Ghosh S, Rose C, Montano-Loza AJ. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int. 2018;12:377-386. [PMID: 29881992 DOI: 10.1007/s12072-018-9875-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 16.5] [Reference Citation Analysis]
12 Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2017;19:821-36. [PMID: 28560717 DOI: 10.1002/ejhf.872] [Cited by in Crossref: 127] [Cited by in F6Publishing: 101] [Article Influence: 25.4] [Reference Citation Analysis]
13 Djiambou-Nganjeu H. Relationship Between Portal HTN and Cirrhosis as a Cause for Diabetes. J Transl Int Med 2019;7:79-83. [PMID: 31380241 DOI: 10.2478/jtim-2019-0009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therap Adv Gastroenterol 2016;9:473-82. [PMID: 27366216 DOI: 10.1177/1756283X16644249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
15 Zhu J, Qi X, Yu H, Yoshida EM, Mendez-Sanchez N, Zhang X, Wang R, Deng H, Li J, Han D, Guo X. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. United European Gastroenterol J. 2018;6:1179-1187. [PMID: 30288280 DOI: 10.1177/2050640618773564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
16 Cittolin-santos G, Guazzelli P, Nonose Y, Almeida R, Fontella F, Pasquetti M, Ferreira-lima F, Lazzaroto G, Berlezi R, Osvaldt A, Calcagnotto M, de Assis A, Souza D. Behavioral, Neurochemical and Brain Oscillation Abnormalities in an Experimental Model of Acute Liver Failure. Neuroscience 2019;401:117-29. [DOI: 10.1016/j.neuroscience.2018.12.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Weis S, Büttner A. Nutritional and systemic metabolic disorders. Handb Clin Neurol 2017;145:167-73. [PMID: 28987167 DOI: 10.1016/B978-0-12-802395-2.00012-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Fabrellas N, Moreira R, Carol M, Cervera M, de Prada G, Perez M, Vazquez E, Sola M, Sancho R, Juanola A, Pose E, Solé C, Graupera I, Solà E, Kamath PS, Ginès P. Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. Clin Transl Gastroenterol 2020;11:e00159. [PMID: 32352686 DOI: 10.14309/ctg.0000000000000159] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
19 Yang F, Wu L, Xu W, Liu Y, Zhen L, Ning G, Song J, Jiao Q, Zheng Y, Chen T, Xie C, Peng L. Diverse Effects of the NTCP p.Ser267Phe Variant on Disease Progression During Chronic HBV Infection and on HBV preS1 Variability. Front Cell Infect Microbiol 2019;9:18. [PMID: 30881922 DOI: 10.3389/fcimb.2019.00018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep 2021;3:100264. [PMID: 34013182 DOI: 10.1016/j.jhepr.2021.100264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Bruyneel M, Sersté T. Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges. Nat Sci Sleep 2018;10:369-75. [PMID: 30464664 DOI: 10.2147/NSS.S186665] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
22 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Kakihara A, Maenohara S, Tokushige K, Ido A. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. Hepatol Res 2021;51:445-60. [PMID: 33533150 DOI: 10.1111/hepr.13622] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev 2015;:CD001939. [PMID: 26377410 DOI: 10.1002/14651858.CD001939.pub3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
24 Yoh K, Nishikawa H, Enomoto H, Iwata Y, Ishii A, Yuri Y, Ishii N, Miyamoto Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Effect of physical exercise on sarcopaenia in patients with overt hepatic encephalopathy: a study protocol for a randomised controlled trial. BMJ Open Gastroenterol 2017;4:e000185. [PMID: 29259793 DOI: 10.1136/bmjgast-2017-000185] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;7:CD002798. [PMID: 28745801 DOI: 10.1002/14651858.CD002798.pub3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Testino G, Vignoli T, Patussi V, Scafato E, Caputo F; SIA board (Appendix A) and the external expert supervisors (Appendix B). Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020;52:21-32. [PMID: 31757596 DOI: 10.1016/j.dld.2019.09.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
27 Tchan M. Hyperammonemia and lactic acidosis in adults: Differential diagnoses with a focus on inborn errors of metabolism. Rev Endocr Metab Disord. 2018;19:69-79. [PMID: 29497930 DOI: 10.1007/s11154-018-9444-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
28 Agiasotelli D, Alexopoulou A, Vasilieva L, Kalpakou G, Papadaki S, Dourakis SP. Evaluation of neutrophil/leukocyte ratio and organ failure score as predictors of reversibility and survival following an acute-on-chronic liver failure event: Predictors of long-term survival in ACLF. Hepatol Res 2016;46:514-20. [DOI: 10.1111/hepr.12582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
29 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev 2019;6:CD012334. [PMID: 31204790 DOI: 10.1002/14651858.CD012334.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
31 Stokes CS, Goh ET, Vilstrup H, Morgan MY, Gluud LL; Cochrane Hepato-Biliary Group. L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012410] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Anand L, Bihari C, Kedarisetty CK, Rooge SB, Kumar D, Shubham S, Kumar G, Sahney A, Sharma MK, Maiwall R, Kumar A, Sarin SK. Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis. Liver Int 2019;39:115-26. [PMID: 29962032 DOI: 10.1111/liv.13923] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
33 Yang C, Liu J, Shi Q, Huang S, Zhou C, Wang Y, Li T, Chen Y, Xiong B. Effect of splenectomy on the outcomes in patients with cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol 2021. [PMID: 33973270 DOI: 10.1111/jgh.15543] [Reference Citation Analysis]
34 Orr JG, Currie CJ, Berni E, Goel A, Moriarty KJ, Sinha A, Gordon F, Dethier A, Dillon JF, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall RJ, Hudson M. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α. Liver Int 2016;36:1295-303. [PMID: 26950766 DOI: 10.1111/liv.13111] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
35 Liu J, Ma J, Yang C, Ye T, Meng J, Shi Q, Xiong B. Impact of TIPS on Splenic Volume and Thrombocytopenia. AJR Am J Roentgenol 2021;216:698-703. [PMID: 33439047 DOI: 10.2214/AJR.20.22958] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Dimitrova M, Pavlov K, Mitov K, Genov J, Petrova GI. Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria. Front Med (Lausanne) 2017;4:125. [PMID: 28824914 DOI: 10.3389/fmed.2017.00125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Solinas A, Piras MR, Deplano A. Cognitive dysfunction and hepatitis C virus infection. World J Hepatol 2015; 7(7): 922-925 [PMID: 25954475 DOI: 10.4254/wjh.v7.i7.922] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
38 Djiambou-Nganjeu H. Hepatic Encephalopathy in Patients in Lviv (Ukraine). J Transl Int Med. 2018;6:146-151. [PMID: 30425951 DOI: 10.2478/jtim-2018-0021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Mosoni C, Dionisi T, Vassallo GA, Mirijello A, Tarli C, Antonelli M, Sestito L, Rando MM, Tosoni A, De Cosmo S, Gasbarrini A, Addolorato G. Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Front Psychiatry 2018;9:474. [PMID: 30327620 DOI: 10.3389/fpsyt.2018.00474] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
40 Duah A, Agyei-Nkansah A, Osei-Poku F, Duah F, Ampofo-Boobi D, Peprah B. The Prevalence, Predictors, and In-Hospital Mortality of Hepatic Encephalopathy in Patients with Liver Cirrhosis Admitted at St. Dominic Hospital in Akwatia, Ghana. Can J Gastroenterol Hepatol 2020;2020:8816522. [PMID: 33425806 DOI: 10.1155/2020/8816522] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Giménez-Garzó C, Garcés JJ, Urios A, Mangas-Losada A, García-García R, González-López O, Giner-Durán R, Escudero-García D, Serra MA, Soria E, Felipo V, Montoliu C. The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients. PLoS One 2017;12:e0171211. [PMID: 28146589 DOI: 10.1371/journal.pone.0171211] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
42 Weiss N, Attali V, Bouzbib C, Thabut D. Altered distal-proximal temperature gradient as a possible explanation for sleep-wake disturbances in cirrhotic patients. Liver Int 2017;37:1776-9. [PMID: 29149489 DOI: 10.1111/liv.13590] [Reference Citation Analysis]
43 Shawcross DL, Dunk AA, Jalan R, Kircheis G, de Knegt RJ, Laleman W, Ramage JK, Wedemeyer H, Morgan IE; New Insights Steering Committee. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016;28:146-152. [PMID: 26600154 DOI: 10.1097/meg.0000000000000529] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
44 Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, Monster-Simons MH, van Putten SA, Metselaar HJ, Taxis K, Borgsteede SD. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open 2016;6:e012991. [PMID: 27733414 DOI: 10.1136/bmjopen-2016-012991] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
45 Kinny-Köster B, Bartels M, Becker S, Scholz M, Thiery J, Ceglarek U, Kaiser T. Plasma Amino Acid Concentrations Predict Mortality in Patients with End-Stage Liver Disease. PLoS One 2016;11:e0159205. [PMID: 27410482 DOI: 10.1371/journal.pone.0159205] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
46 Claeys W, Van Hoecke L, Lefere S, Geerts A, Verhelst X, Van Vlierberghe H, Degroote H, Devisscher L, Vandenbroucke RE, Van Steenkiste C. The neurogliovascular unit in hepatic encephalopathy. JHEP Rep 2021;3:100352. [PMID: 34611619 DOI: 10.1016/j.jhepr.2021.100352] [Reference Citation Analysis]
47 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;CD003044. [PMID: 27153247 DOI: 10.1002/14651858.cd003044.pub4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
48 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
49 Cao JM, Yang JQ, Ming ZQ, Wu JL, Yang LQ, Chen TW, Li R, Ou J, Zhang XM, Mu QW, Li HJ, Hu J. A radiomics model of liver CT to predict risk of hepatic encephalopathy secondary to hepatitis B related cirrhosis.Eur J Radiol. 2020;130:109201. [PMID: 32738462 DOI: 10.1016/j.ejrad.2020.109201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Ridola L, Riggio O, Gioia S, Faccioli J, Nardelli S. Clinical management of type C hepatic encephalopathy. United European Gastroenterol J 2020;8:536-43. [PMID: 32213035 DOI: 10.1177/2050640620909675] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
51 Lichvar AB, Hedges A, Benedict NJ, Donihi AC. Combination of a Flipped Classroom Format and a Virtual Patient Case to Enhance Active Learning in a Required Therapeutics Course. Am J Pharm Educ 2016;80:175. [PMID: 28179724 DOI: 10.5688/ajpe8010175] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
52 Grover VP, Crossey MM, Fitzpatrick JA, Saxby BK, Shaw R, Waldman AD, Morgan MY, Taylor-Robinson SD. Quantitative magnetic resonance imaging in patients with cirrhosis: a cross-sectional study. Metab Brain Dis 2016;31:1315-25. [PMID: 26251205 DOI: 10.1007/s11011-015-9716-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;5:CD001939. [PMID: 28518283 DOI: 10.1002/14651858.cd001939.pub4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
54 Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol 2019; 25(33): 4814-4834 [PMID: 31543676 DOI: 10.3748/wjg.v25.i33.4814] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
55 Basu PP, Shah NJ. Clinical and Neurologic Manifestation of Minimal Hepatic Encephalopathy and Overt Hepatic Encephalopathy. Clin Liver Dis. 2015;19:461-472. [PMID: 26195201 DOI: 10.1016/j.cld.2015.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
56 Alexopoulou A, Vasilieva L, Mani I, Agiasotelli D, Pantelidaki H, Dourakis SP. Single center validation of mortality scores in patients with acute decompensation of cirrhosis with and without acute-on-chronic liver failure. Scandinavian Journal of Gastroenterology 2017;52:1385-90. [DOI: 10.1080/00365521.2017.1369560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
57 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410. [PMID: 29762873 DOI: 10.1002/14651858.cd012410.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
58 Pinto RB, Schneider ACR, Silveira TRD. Cirrhosis in children and adolescents: An overview. World J Hepatol 2015; 7(3): 392-405 [PMID: 25848466 DOI: 10.4254/wjh.v7.i3.392] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
59 Liu J, Meng J, Zhou C, Shi Q, Yang C, Ma J, Chen M, Xiong B. A new choice of stent for transjugular intrahepatic portosystemic shunt creation: Viabahn ePTFE covered stent/bare metal stent combination. J Interv Med 2021;4:32-8. [PMID: 34805945 DOI: 10.1016/j.jimed.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bjerring PN, Morgan MY, Vilstrup H, Nielsen SM, Christensen R, Gluud LL; Cochrane Hepato-Biliary Group. Medical interventions for prevention and treatment of hepatic encephalopathy in adults with cirrhosis: a network meta-analysis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013241] [Reference Citation Analysis]
61 Krag A, Schuchmann M, Sodatonou H, Pilot J, Whitehouse J, Strasser SI, Hudson M. Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-α (PROSPER): an observational study among 550 patients. Hepatol Med Policy 2018;3:4. [PMID: 30288327 DOI: 10.1186/s41124-017-0029-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
62 Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget. 2017;8:36161-36170. [PMID: 28212535 DOI: 10.18632/oncotarget.15322] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
63 Paternostro R, Lampichler K, Bardach C, Asenbaum U, Landler C, Bauer D, Mandorfer M, Schwarzer R, Trauner M, Reiberger T, Ferlitsch A. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver Int. 2019;39:2374-2385. [PMID: 31421002 DOI: 10.1111/liv.14217] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
64 Hjorth M, Svanberg A, Sjöberg D, Rorsman F, Kaminsky E. Liver cirrhosis turns life into an unpredictable roller coaster: A qualitative interview study. J Clin Nurs 2020;29:4532-43. [PMID: 32888238 DOI: 10.1111/jocn.15478] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Stukova NY, Kucheryavyi YA, Maevskaya EA, Maev IV. [Ultrasound elastography of the liver for assessing the risk of complications of its cirrhosis of different etiologies]. Ter Arkh 2017;89:38-44. [PMID: 28281514 DOI: 10.17116/terarkh201789238-44] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Bar N, Levy S, Deutsch L, Leshno M, Rabinowich L, Younis F, Shibolet O, Katchman H. Hepatitis C related cognitive impairment: Impact of viral and host factors and response to therapy. J Viral Hepat 2021;28:870-7. [PMID: 33624351 DOI: 10.1111/jvh.13492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Zacharias HD, Zacharias AP, Oliveira Ferreira A, Morgan MY, Gluud LL; Cochrane Hepato-Biliary Group. Ammonia scavenging agents for people with cirrhosis and hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012334] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Salman T, Elsabaawy M, Omar M, Afify M, Elezawy H, Ghanem S, Abdelraouf O, Rewisha E, Shebl N. Evaluation of different diagnostic modalities of minimal hepatic encephalopathy in cirrhotic patients: case-control study. Clin Exp Hepatol 2021;7:312-9. [PMID: 34712834 DOI: 10.5114/ceh.2021.109292] [Reference Citation Analysis]
69 Praktiknjo M, Simón-talero M, Römer J, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, Llop E, Maurer MH, Zipprich A, Triolo M, Maleux G, Fialla AD, Dam C, Vidal-gonzález J, Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, López M, Jansen C, Chang J, Schierwagen R, Uschner F, Kukuk G, Meyer C, Thomas D, Wolter K, Strassburg CP, Laleman W, La Mura V, Ripoll C, Berzigotti A, Calleja JL, Tandon P, Hernandez-gea V, Reiberger T, Albillos A, Tsochatzis EA, Krag A, Genescà J, Trebicka J, Quiroga S, Yu D, Téllez L, Mandorfer M, Garcia-pagan JC, Berbel C, Ferrusquia J, Ble M, Garcia-criado MA, Belmonte E, Ney M, Margini C, Casu S, Murgia G, Ludwig C, Stangl F. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology 2020;72:1140-50. [DOI: 10.1016/j.jhep.2019.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 16.0] [Reference Citation Analysis]
70 Hjorth M, Sjöberg D, Svanberg A, Kaminsky E, Langenskiöld S, Rorsman F. Nurse-led clinic for patients with liver cirrhosis-effects on health-related quality of life: study protocol of a pragmatic multicentre randomised controlled trial. BMJ Open 2018;8:e023064. [PMID: 30337316 DOI: 10.1136/bmjopen-2018-023064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
71 Degré D, Stauber RE, Englebert G, Sarocchi F, Verset L, Rainer F, Spindelboeck W, Njimi H, Trépo E, Gustot T, Lackner C, Deltenre P, Moreno C. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function <32. J Hepatol 2020;72:636-42. [PMID: 31954208 DOI: 10.1016/j.jhep.2019.12.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
72 Liu J, Shi Q, Xiao S, Zhou C, Zhou B, Yuan F, Zheng C, Lin S, Qian K, Feng G, Xiong B. Using transjugular intrahepatic portosystemic shunt as the first-line therapy in secondary prophylaxis of variceal hemorrhage. J Gastroenterol Hepatol 2020;35:278-83. [PMID: 31222830 DOI: 10.1111/jgh.14761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
73 Oliveira AM, Branco JC, Barosa R, Rodrigues JA, Ramos L, Martins A, Karvellas CJ, Cardoso FS. Clinical and microbiological characteristics associated with mortality in spontaneous bacterial peritonitis: a multicenter cohort study. Eur J Gastroenterol Hepatol. 2016;28:1216-1222. [PMID: 27391170 DOI: 10.1097/meg.0000000000000700] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
74 Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450. [PMID: 30444745 DOI: 10.1097/meg.0000000000001311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 7.3] [Reference Citation Analysis]
75 Bai Z, Guo X, Tacke F, Li Y, Li H, Qi X. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization. Therap Adv Gastroenterol 2019;12:1756284819881302. [PMID: 31636711 DOI: 10.1177/1756284819881302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
76 García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2020;2:100122. [PMID: 32671331 DOI: 10.1016/j.jhepr.2020.100122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
77 Simón-talero M, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, Llop E, Praktiknjo M, Maurer MH, Zipprich A, Triolo M, Vangrinsven G, Garcia-martinez R, Dam A, Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, Lopez M, Kukuk G, Krag A, Bañares R, Laleman W, La Mura V, Ripoll C, Berzigotti A, Trebicka J, Calleja JL, Tandon P, Hernandez-gea V, Reiberger T, Albillos A, Tsochatzis EA, Augustin S, Genescà J, Quiroga S, Yu D, Téllez L, Mandorfer M, Garcia-pagan JC, Berbel C, Ferrusquia J, Ble M, Garcia-criado MA, Belmonte E, Ney M, Margini C, Casu S, Murgia G, Ludwig C, Rönsch M, Stoevesandt D, Carrion L, Botella ER. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology 2018;154:1694-1705.e4. [DOI: 10.1053/j.gastro.2018.01.028] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 16.5] [Reference Citation Analysis]
78 Dellatore P, Cheung M, Mahpour NY, Tawadros A, Rustgi VK. Clinical Manifestations of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:189-96. [DOI: 10.1016/j.cld.2020.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 De Gottardi A, Greenslade LC, Walker MA. Hepatic encephalopathy: A call to action to optimize patient outcomes. Dig Liver Dis 2016;48:820-2. [PMID: 27133209 DOI: 10.1016/j.dld.2016.03.030] [Reference Citation Analysis]
80 Bothou C, Rüschenbaum S, Kubesch A, Quenstedt L, Schwarzkopf K, Welsch C, Zeuzem S, Welzel TM, Lange CM. Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis. J Clin Med 2020;9:E1263. [PMID: 32357568 DOI: 10.3390/jcm9051263] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
81 Marasco G, Dajti E, Ravaioli F, Brocchi S, Rossini B, Alemanni LV, Peta G, Bartalena L, Golfieri R, Festi D, Colecchia A, Renzulli M. Clinical impact of sarcopenia assessment in patients with liver cirrhosis. Expert Rev Gastroenterol Hepatol 2021;15:377-88. [PMID: 33196344 DOI: 10.1080/17474124.2021.1848542] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Liu J, Yang C, Huang S, Zhou C, Shi Q, Qian K, Song S, Xiong B. The combination of balloon-assisted antegrade transvenous obliteration and transjugular intrahepatic portosystemic shunt for the management of cardiofundal varices hemorrhage. Eur J Gastroenterol Hepatol. 2020;32:656-662. [PMID: 32175982 DOI: 10.1097/meg.0000000000001705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
83 Goh ET, Andersen ML, Morgan MY, Gluud LL. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev 2017;8:CD002798. [PMID: 28796283 DOI: 10.1002/14651858.CD002798.pub4] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
84 Addolorato G, Vassallo GA, Mirijello A, Gasbarrini A. Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows. Neurotherapeutics 2020;17:127-41. [PMID: 31713188 DOI: 10.1007/s13311-019-00802-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
85 Künzler-heule P, Beckmann S, Mahrer-imhof R, Semela D, Händler-schuster D. Being an informal caregiver for a relative with liver cirrhosis and overt hepatic encephalopathy: a phenomenological study. J Clin Nurs 2016;25:2559-68. [DOI: 10.1111/jocn.13298] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
86 Zeng X, Li XX, Shi PM, Zhang YY, Song Y, Liu Q, Wei L, Bajaj JS, Zhu YH, Li Y, Gu Y, Xie WF, Liu YL. Utility of the EncephalApp Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients. J Gastroenterol Hepatol 2019;34:1843-50. [PMID: 30861191 DOI: 10.1111/jgh.14656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
87 Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, Marchesini G, Merli M, Ponziani FR, Riggio O, Scarpignato C. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019;51:190-205. [PMID: 30606696 DOI: 10.1016/j.dld.2018.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
88 Solà E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, Uschner F, de Wit K, Zaccherini G, Alessandria C, Beuers U, Caraceni P, Francoz C, Mookerjee RP, Trebicka J, Vargas V, Serra M, Torres F, Montagnese S, Krag A, Hernaez R, Korenjak M, Watson H, Abraldes JG, Kamath PS, Ginès P; LiverHope Consortium Investigators. Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. J Hepatol 2021;74:200-19. [PMID: 32896580 DOI: 10.1016/j.jhep.2020.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
89 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
90 Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol 2020; 26(18): 2221-2231 [PMID: 32476788 DOI: 10.3748/wjg.v26.i18.2221] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
91 Mallet M, Haq M, Tripon S, Bernard M, Benosman H, Thabut D, Rudler M. Elevated procalcitonin is associated with bacterial infection during acute liver failure only when unrelated to acetaminophen intoxication. Eur J Gastroenterol Hepatol. 2017;29:811-816. [PMID: 28272093 DOI: 10.1097/meg.0000000000000862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
92 Sidhu GS, Go A, Attar BM, Mutneja HR, Arora S, Patel SA. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review. BMJ Open Gastroenterol. 2017;4:e000154. [PMID: 28944070 DOI: 10.1136/bmjgast-2017-000154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
93 DeMorrow S. Bile Acids in Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:117-24. [PMID: 30774268 DOI: 10.1016/j.jceh.2018.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
94 Jeong JH, Park IS, Kim DH, Kim SC, Kang C, Lee SH, Kim TY, Lee SB. CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis. Medicine (Baltimore). 2016;95:e3935. [PMID: 27367990 DOI: 10.1097/md.0000000000003935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
95 Rout G, Sharma S, Gunjan D, Kedia S, Saraya A, Nayak B, Singh V, Kumar R, Shalimar. Development and Validation of a Novel Model for Outcomes in Patients with Cirrhosis and Acute Variceal Bleeding. Dig Dis Sci 2019;64:2327-37. [PMID: 30830520 DOI: 10.1007/s10620-019-05557-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
96 Williams E, Chu C, DeMorrow S. A critical review of bile acids and their receptors in hepatic encephalopathy. Anal Biochem 2021;:114436. [PMID: 34715070 DOI: 10.1016/j.ab.2021.114436] [Reference Citation Analysis]
97 Muir AJ. Understanding the Complexities of Cirrhosis. Clinical Therapeutics 2015;37:1822-36. [DOI: 10.1016/j.clinthera.2015.05.507] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
98 Grover VP, Tognarelli JM, Massie N, Crossey MM, Cook NA, Taylor-Robinson SD. The why and wherefore of hepatic encephalopathy. Int J Gen Med 2015;8:381-90. [PMID: 26719720 DOI: 10.2147/IJGM.S86854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
99 Hsu SJ, Zhang C, Jeong J, Lee SI, McConnell M, Utsumi T, Iwakiri Y. Enhanced Meningeal Lymphatic Drainage Ameliorates Neuroinflammation and Hepatic Encephalopathy in Cirrhotic Rats. Gastroenterology 2021;160:1315-1329.e13. [PMID: 33227282 DOI: 10.1053/j.gastro.2020.11.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Martín-llahí M, Albillos A, Bañares R, Berzigotti A, García-criado MÁ, Genescà J, Hernández-gea V, Llop-herrera E, Masnou-ridaura H, Mateo J, Navascués CA, Puente Á, Romero-gutiérrez M, Simón-talero M, Téllez L, Turon F, Villanueva C, Zarrabeitia R, García-pagán JC. Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado. Gastroenterología y Hepatología 2017;40:538-80. [DOI: 10.1016/j.gastrohep.2017.03.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
101 Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015;2:CD001939. [PMID: 25715177 DOI: 10.1002/14651858.cd001939.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
102 Mallet M, Weiss N, Thabut D, Rudler M. Why and when to measure ammonemia in cirrhosis? Clin Res Hepatol Gastroenterol 2018;42:505-11. [PMID: 29551609 DOI: 10.1016/j.clinre.2018.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
103 McMillin M, Grant S, Frampton G, Petrescu AD, Williams E, Jefferson B, Thomas A, Brahmaroutu A, DeMorrow S. Elevated circulating TGFβ1 during acute liver failure activates TGFβR2 on cortical neurons and exacerbates neuroinflammation and hepatic encephalopathy in mice. J Neuroinflammation 2019;16:69. [PMID: 30940161 DOI: 10.1186/s12974-019-1455-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
104 López A, Chavarría R, Oviedo G. Therapeutic dilemma: alcohol withdrawal syndrome and concurrent hepatic encephalopathy. A case report. Rev Colomb Psiquiatr (Engl Ed) 2021;50:52-6. [PMID: 33648698 DOI: 10.1016/j.rcp.2019.10.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Fernández J, Aracil C, Solà E, Soriano G, Cinta Cardona M, Coll S, Genescà J, Hombrados M, Morillas R, Martín-Llahí M, Pardo A, Sánchez J, Vargas V, Xiol X, Ginès P. [Evaluation and treatment of the critically ill cirrhotic patient]. Gastroenterol Hepatol 2016;39:607-26. [PMID: 26778768 DOI: 10.1016/j.gastrohep.2015.09.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
106 Cao Q, Yu C, Yang S, Cao H, Chen P, Deng M, Li L. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. Hepatobiliary & Pancreatic Diseases International 2018;17:9-16. [DOI: 10.1016/j.hbpd.2018.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
107 Fischer J, Silva TE, Soares e Silva PE, Colombo BS, Silva MC, Wildner LM, Bazzo ML, Rateke ECM, Frode TS, Mello SVD, Rosa JS, Dantas-correa EB, Narciso-schiavon JL, Schiavon LL. From stable disease to acute-on-chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis. Cytokine 2017;91:162-9. [DOI: 10.1016/j.cyto.2016.12.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
108 Suzuki H, Sezaki H, Suzuki F, Kasuya K, Sano T, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, Saitoh S, Kobayashi M, Arase Y, Ikeda K, Suzuki Y, Kumada H. Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatol Res 2019;49:1406-13. [DOI: 10.1111/hepr.13415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Beg S, Curtis S, Shariff M. Patient education and its effect on self-management in cirrhosis: a pilot study. Eur J Gastroenterol Hepatol 2016;28:582-7. [PMID: 27015016 DOI: 10.1097/MEG.0000000000000579] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
110 Maimone S, Saffioti F, Oliva G, Di Benedetto A, Alibrandi A, Filomia R, Caccamo G, Saitta C, Cacciola I, Pitrone C, Squadrito G, Raimondo G. Erectile dysfunction in compensated liver cirrhosis. Digestive and Liver Disease 2019;51:843-9. [DOI: 10.1016/j.dld.2018.10.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 Bernal W, Karvellas C, Saliba F, Saner FH, Meersseman P. Intensive care management of acute-on-chronic liver failure. J Hepatol 2021;75 Suppl 1:S163-77. [PMID: 34039487 DOI: 10.1016/j.jhep.2020.10.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, Zaccherini G, Alessandria C, Angeli P, Bernardi M, Beuers U, Caraceni P, Durand F, Mookerjee RP, Trebicka J, Vargas V, Andrade RJ, Carol M, Pich J, Ferrero J, Domenech G, Llopis M, Torres F, Kamath PS, Abraldes JG, Solà E, Ginès P. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol 2020;5:31-41. [PMID: 31607677 DOI: 10.1016/S2468-1253(19)30320-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 8.3] [Reference Citation Analysis]
113 Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044. [PMID: 27089005 DOI: 10.1002/14651858.cd003044.pub3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
114 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
115 Fründt T, Kuballa L, Lütgehetman M, Nörz D, Arend H, Brehm TT, Schulze Zur Wiesch J, Horvatits T, Horvatits K, Huber S, Wege H, Kluwe J. Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic. PLoS One 2021;16:e0258450. [PMID: 34941875 DOI: 10.1371/journal.pone.0258450] [Reference Citation Analysis]
116 Ponziani FR, Funaro B, Lupascu A, Ainora ME, Garcovich M, Caracciolo G, Quadarella A, Nesci A, Riccardi L, Gasbarrini A, Pompili M, Zocco MA. Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. Sci Rep 2019;9:15373. [PMID: 31653939 DOI: 10.1038/s41598-019-51867-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Kodali S, Mcguire BM. Diagnosis and Management of Hepatic Encephalopathy in Fulminant Hepatic Failure. Clinics in Liver Disease 2015;19:565-76. [DOI: 10.1016/j.cld.2015.04.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
118 Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:157-74. [DOI: 10.1016/j.cld.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
119 Ferreira MDF, Salavati Schmitz S, Schoenebeck JJ, Clements DN, Campbell SM, Gaylor DE, Mellanby RJ, Gow AG, Salavati M. Lactulose drives a reversible reduction and qualitative modulation of the faecal microbiota diversity in healthy dogs. Sci Rep 2019;9:13350. [PMID: 31527716 DOI: 10.1038/s41598-019-50090-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Maggi DC, Borgonovo A, Bansho ET, Soares-silva PE, Silva TE, Colombo BS, Wildner LM, Bazzo ML, Dantas-correa EB, Narciso-schiavon JL, Schiavon LL. Serial assessment of hepatic encephalopathy in patients hospitalised for acute decompensation of cirrhosis. Annals of Hepatology 2019;18:331-7. [DOI: 10.1016/j.aohep.2018.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
121 Oey RC, van Tilburg L, Erler NS, Metselaar HJ, Spaander MCW, van Buuren HR, de Man RA. The Yield and Safety of Screening Colonoscopy in Patients Evaluated for Liver Transplantation. Hepatology. 2019;69:2598-2607. [PMID: 30767249 DOI: 10.1002/hep.30562] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
122 Jiang TT, Liu XL, Jiang YY, Wang XB, Yang ZY. Minimal Hepatic Encephalopathy and Biejia-Ruangan Are Associated with First Hospital Readmission in Nonalcoholic Cirrhosis Patients. Evid Based Complement Alternat Med 2021;2021:6652858. [PMID: 34055016 DOI: 10.1155/2021/6652858] [Reference Citation Analysis]
123 Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS One. 2016;11:e0146076. [PMID: 26745876 DOI: 10.1371/journal.pone.0146076] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
124 Vidal-González J, Quiroga S, Simón-Talero M, Genescà J. Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem. Therap Adv Gastroenterol 2020;13:1756284820961287. [PMID: 33062057 DOI: 10.1177/1756284820961287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
125 Santos LA, Lima TB, Ietsugu MDV, Nunes HRDC, Qi X, Romeiro FG. Anthropometric measures associated with sarcopenia in outpatients with liver cirrhosis. Nutr Diet 2019;76:613-9. [DOI: 10.1111/1747-0080.12523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
126 Yuan LT, Chuah SK, Yang SC, Liang CM, Wu CK, Tai WC, Hung TH, Nguang SH, Wang JW, Tseng KL, Ku MK, Hsu PI, Wu DC, Hsu CN. Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis. PLoS One. 2018;13:e0197127. [PMID: 29746564 DOI: 10.1371/journal.pone.0197127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
127 Abdel Moneim M, Abdelaziz DH, Ibrahim Nagy Y, Abdel Baki A, Attia AS, Sabry N. Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis. Int J Clin Pract 2021;75:e14807. [PMID: 34487412 DOI: 10.1111/ijcp.14807] [Reference Citation Analysis]
128 Grgurevic I, Trkulja V, Bozin T, Madir A, Miletic M, Marusic S, Skrlin J, Sestan Crnek S, Dobrovic K. Infection as a predictor of mortality in decompensated liver cirrhosis: exploring the relationship to severity of liver failure. Eur J Gastroenterol Hepatol. 2019;. [PMID: 31895905 DOI: 10.1097/meg.0000000000001667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Stern RA, Mozdziak PE. Differential ammonia metabolism and toxicity between avian and mammalian species, and effect of ammonia on skeletal muscle: A comparative review. J Anim Physiol Anim Nutr (Berl) 2019;103:774-85. [PMID: 30860624 DOI: 10.1111/jpn.13080] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
130 Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, Abraldes JG, Bosch J, Sanchez-Tapias JM, Forns X, García-Pagán JC. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clin Gastroenterol Hepatol 2015;13:1846-1853.e1. [PMID: 25912838 DOI: 10.1016/j.cgh.2015.04.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
131 Tadevosyan A, Kornbluth J. Brain Herniation and Intracranial Hypertension. Neurol Clin 2021;39:293-318. [PMID: 33896520 DOI: 10.1016/j.ncl.2021.02.005] [Reference Citation Analysis]
132 Long L, Li H, Deng G, Wang X, Lu S, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Ren H, Shang J, Li H, Wang S, Zheng Y, Yan H, Yin S, Tan W, Zhang Q, Zheng X, Chen J, Luo S, Zhao J, Yuan W, Li T, Zheng R, Liu J, Liu X, Gu W, Li S, Mei X, Chen R, Huang Y. Impact of Hepatic Encephalopathy on Clinical Characteristics and Adverse Outcomes in Prospective and Multicenter Cohorts of Patients With Acute-on-Chronic Liver Diseases. Front Med (Lausanne) 2021;8:709884. [PMID: 34409052 DOI: 10.3389/fmed.2021.709884] [Reference Citation Analysis]
133 Elzubeir A, Alam SM. Letter to editor ‘prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with Rifaxamin’. World J Gastroenterol 2020; 26(44): 7085-7087 [PMID: 33311952 DOI: 10.3748/wjg.v26.i44.7085] [Reference Citation Analysis]
134 Jawaro T, Yang A, Dixit D, Bridgeman MB. Management of Hepatic Encephalopathy: A Primer. Ann Pharmacother. 2016;50:569-577. [PMID: 27126547 DOI: 10.1177/1060028016645826] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
135 Schindler P, Seifert L, Masthoff M, Riegel A, Köhler M, Wilms C, Schmidt HH, Heinzow H, Wildgruber M. TIPS Modification in the Management of Shunt-Induced Hepatic Encephalopathy: Analysis of Predictive Factors and Outcome with Shunt Modification. J Clin Med 2020;9:E567. [PMID: 32092979 DOI: 10.3390/jcm9020567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
136 Mwalitsa JP, Maimone S, Filomia R, Alibrandi A, Saitta C, Caccamo G, Cacciola I, Spinella R, Oliva G, Lembo T. Atrial fibrillation in patients with cirrhosis. Liver Int. 2016;36:395-400. [PMID: 26235424 DOI: 10.1111/liv.12928] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
137 Han X, Luo Z, Wang W, Zheng P, Li T, Mei Z, Wang J. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Front Pharmacol 2021;12:696065. [PMID: 34690751 DOI: 10.3389/fphar.2021.696065] [Reference Citation Analysis]
138 Téllez L, Rodríguez de Santiago E, Albillos A. Fontan-associated Liver Disease. Rev Esp Cardiol (Engl Ed) 2018;71:192-202. [PMID: 29433942 DOI: 10.1016/j.rec.2017.10.052] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
139 Oey RC, Aarts P, Erler NS, Metselaar HJ, Lakenman PL, Riemslag Baas-van der Ree S, van Kemenade MC, van Buuren HR, de Man RA. Identification and prognostic impact of malnutrition in a population screened for liver transplantation. Clinical Nutrition ESPEN 2020;36:36-44. [DOI: 10.1016/j.clnesp.2020.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Dhaliwal A, Armstrong MJ, Tripathi D. Patient Selection for Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion in Variceal Bleeding and Refractory Ascites. Curr Hepatology Rep 2017;16:241-9. [DOI: 10.1007/s11901-017-0361-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
141 Kimer N, Gluud LL, Pedersen JS, Tavenier J, Møller S, Bendtsen F. The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis. Transl Gastroenterol Hepatol 2021;6:8. [PMID: 33409402 DOI: 10.21037/tgh.2020.02.14] [Reference Citation Analysis]
142 Al-Dury S, Molinaro A, Hedenström P. Propranolol-induced hallucinations mimicking encephalopathy in a patient with liver cirrhosis. Scand J Gastroenterol 2021;56:829-31. [PMID: 33961526 DOI: 10.1080/00365521.2021.1919198] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Pathania A, Rawat A, Dahiya SS, Dhanda S, Barnwal RP, Baishya B, Sandhir R. 1H NMR-Based Metabolic Signatures in the Liver and Brain in a Rat Model of Hepatic Encephalopathy. J Proteome Res 2020;19:3668-79. [PMID: 32660248 DOI: 10.1021/acs.jproteome.0c00165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Yu LH, Yu WL, Zhao T, Wu MC, Fu XH, Zhang YJ. Post-operative delayed elevation of ALT correlates with early death in patients with HBV-related hepatocellular carcinoma and Post-hepatectomy Liver Failure. HPB (Oxford) 2018;20:321-6. [PMID: 29373299 DOI: 10.1016/j.hpb.2017.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
145 Kandiah PA, Kumar G. Hepatic Encephalopathy-the Old and the New.Crit Care Clin. 2016;32:311-329. [PMID: 27339673 DOI: 10.1016/j.ccc.2016.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
146 Sawhney R, Jalan R. Liver: the gut is a key target of therapy in hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2015;12:7-8. [PMID: 25348849 DOI: 10.1038/nrgastro.2014.185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
147 Devabhaktuni S, Patkar P, Pooja V, Dhamija S, Gupta N, Chaudhury S, Saldanha D. Differentiation of hepatic encephalopathy from delirium tremens: A case series and review. Ind Psychiatry J 2021;30:S214-20. [PMID: 34908693 DOI: 10.4103/0972-6748.328865] [Reference Citation Analysis]
148 Téllez L, Rodríguez-Santiago E, Albillos A. Fontan-Associated Liver Disease: A Review. Ann Hepatol 2018;17:192-204. [PMID: 29469053 DOI: 10.5604/01.3001.0010.8634] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
149 Agiasotelli D, Alexopoulou A, Vasilieva L, Hadziyannis E, Goukos D, Daikos GL, Dourakis SP. High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis. Liver Int. 2017;37:576-582. [PMID: 27712029 DOI: 10.1111/liv.13264] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
150 Oey RC, Buck LEM, Erler NS, van Buuren HR, de Man RA. The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy. Therap Adv Gastroenterol 2019;12:1756284819858256. [PMID: 31258622 DOI: 10.1177/1756284819858256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
151 Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. Antibiotics (Basel). 2020;9. [PMID: 32235367 DOI: 10.3390/antibiotics9040145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
152 Routhu M, Safka V, Routhu SK, Fejfar T, Jirkovsky V, Krajina A, Cermakova E, Hosak L, Hulek P. Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS). Ann Hepatol. 2017;16:140-148. [PMID: 28051803 DOI: 10.5604/16652681.1226932] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
153 Merli M, Riggio O. Interaction between infection and hepatic encephalopathy. J Hepatol. 2015;62:746-747. [PMID: 25450708 DOI: 10.1016/j.jhep.2014.10.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
154 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
155 Guacho JAL, de Moura DTH, Ribeiro IB, da Ponte Neto AM, Singh S, Tucci MGB, Bernardo WM, de Moura EGH. Propofol vs midazolam sedation for elective endoscopy in patients with cirrhosis: A systematic review and meta-analysis of randomized controlled trials. World J Gastrointest Endosc 2020; 12(8): 241-255 [PMID: 32879659 DOI: 10.4253/wjge.v12.i8.241] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
156 Wang AJ, Peng AP, Li BM, Gan N, Pei L, Zheng XL, Hong JB, Xiao HY, Zhong JW, Zhu X. Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients. World J Gastroenterol 2017; 23(34): 6321-6329 [PMID: 28974899 DOI: 10.3748/wjg.v23.i34.6321] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
157 Yao CK, Fung J, Chu NHS, Tan VPY. Dietary Interventions in Liver Cirrhosis. J Clin Gastroenterol. 2018;52:663-673. [PMID: 29912757 DOI: 10.1097/mcg.0000000000001071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
158 Pelle J, Castelli FA, Rudler M, Alioua I, Colsch B, Fenaille F, Junot C, Thabut D, Weiss N. Metabolomics in the understanding and management of hepatic encephalopathy. Anal Biochem 2022;636:114477. [PMID: 34808106 DOI: 10.1016/j.ab.2021.114477] [Reference Citation Analysis]
159 Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy a critical current review. Hepatol Int. 2018;12:135-147. [PMID: 28770516 DOI: 10.1007/s12072-017-9812-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 11.6] [Reference Citation Analysis]
160 Grant S, McMillin M, Frampton G, Petrescu AD, Williams E, Jaeger V, Kain J, DeMorrow S. Direct Comparison of the Thioacetamide and Azoxymethane Models of Type A Hepatic Encephalopathy in Mice. Gene Expr. 2018;18:171-185. [PMID: 29895352 DOI: 10.3727/105221618x15287315176503] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
161 Tamaoki S, Suzuki H, Okada M, Fukui N, Isobe M, Saito T. Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin. European Journal of Pharmacology 2016;779:168-76. [DOI: 10.1016/j.ejphar.2016.03.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
162 Pagliano P, Boccia G, De Caro F, Esposito S. Bacterial meningitis complicating the course of liver cirrhosis. Infection 2017;45:795-800. [DOI: 10.1007/s15010-017-1039-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
163 Fiati Kenston SS, Song X, Li Z, Zhao J. Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy. J Gastroenterol Hepatol. 2019;34:31-39. [PMID: 30070387 DOI: 10.1111/jgh.14408] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
164 Bai Z, Bernardi M, Yoshida EM, Li H, Guo X, Méndez-Sánchez N, Li Y, Wang R, Deng J, Qi X. Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis. Aging (Albany NY) 2019;11:8502-25. [PMID: 31596729 DOI: 10.18632/aging.102335] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
165 Li M, Zhang Z, Chen Q, Zhou X, Shui D, Huang J. Comparative Effectiveness and Safety of Polyethylene Glycol Electrolyte Solution Versus Lactulose for Treatment of Hepatic Encephalopathy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2022;56:41-8. [PMID: 34739404 DOI: 10.1097/MCG.0000000000001621] [Reference Citation Analysis]
166 El-Karaksy HM, Afifi O, Bakry A, Kader AA, Saber N. A pilot study using lactulose in management of minimal hepatic encephalopathy in children with extrahepatic portal vein obstruction. World J Pediatr 2017;13:70-5. [PMID: 27878780 DOI: 10.1007/s12519-016-0066-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
167 Duah A, Agyei-Nkansah A, Osei-Poku F, Duah F, Addo BP. Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana. PLoS One 2021;16:e0253759. [PMID: 34166471 DOI: 10.1371/journal.pone.0253759] [Reference Citation Analysis]
168 Graupera I, Coll M, Pose E, Elia C, Piano S, Solà E, Blaya D, Huelin P, Solé C, Moreira R, de Prada G, Fabrellas N, Juanola A, Morales-Ruiz M, Sancho-Bru P, Villanueva C, Ginès P. Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. Sci Rep 2017;7:1829. [PMID: 28500294 DOI: 10.1038/s41598-017-01709-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
169 Hanai T, Shiraki M, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis. J Gastroenterol Hepatol 2019;34:1809-16. [PMID: 30779213 DOI: 10.1111/jgh.14635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
170 Augusti L, Franzoni LC, Santos LA, Lima TB, Ietsugu MV, Koga KH, Moriguchi SM, Betting LE, Caramori CA, Silva GF, Romeiro FG. Lower values of handgrip strength and adductor pollicis muscle thickness are associated with hepatic encephalopathy manifestations in cirrhotic patients. Metab Brain Dis 2016;31:909-15. [PMID: 27131802 DOI: 10.1007/s11011-016-9828-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
171 Aby ES, Saab S. Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients. Clinics in Liver Disease 2019;23:589-605. [DOI: 10.1016/j.cld.2019.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
172 Kronsten VT, Shawcross DL. Hepatic encephalopathy and depression in chronic liver disease: is the common link systemic inflammation? Anal Biochem 2021;:114437. [PMID: 34715068 DOI: 10.1016/j.ab.2021.114437] [Reference Citation Analysis]
173 Wong F, Piano S, Singh V, Bartoletti M, Maiwall R, Alessandria C, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, Barea RCR, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bruns T, Yoon EL, Girala M, Pyrsopoulos NT, Kim TH, Yim SY, Juanola A, Gadano A, Angeli P; International Club of Ascites Global Study Group. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J Hepatol 2021;74:330-9. [PMID: 32781201 DOI: 10.1016/j.jhep.2020.07.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
174 Aguirre Valadez JM, Rivera-Espinosa L, Méndez-Guerrero O, Chávez-Pacheco JL, García Juárez I, Torre A. Intestinal permeability in a patient with liver cirrhosis. Ther Clin Risk Manag 2016;12:1729-48. [PMID: 27920543 DOI: 10.2147/TCRM.S115902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
175 Vilar‐gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N. Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology 2019;71:495-509. [DOI: 10.1002/hep.30368] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
176 Pranami D, Sharma R, Pathak H. Lactulose: a prebiotic, laxative and detoxifying agent. Drugs Ther Perspect 2017;33:228-33. [DOI: 10.1007/s40267-017-0384-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
177 Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, Wang YW, Chen Q, Jin GN, Liu TT, Liang JN, Zhu P, Zhu W, Li Y, Zhang BH, Feng H, Zhang WG, Yin ZY, Yu WK, Yang Y, Zhang HQ, Tang ZP, Wang H, Hu JB, Liu JH, Yin P, Chen XP, Zhang B; Tongji Multidisciplinary Team for Treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol 2021;74:1295-302. [PMID: 33347952 DOI: 10.1016/j.jhep.2020.12.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
178 Zhou Y, Ma J, Ju S, Zhang Z, Zhang W, Yang M, Zhou X, Yan Z, Luo J. Efficacy of puncturing different portal vein branch during transjugular intrahepatic portosystemic shunt with 8 mm covered stent: a propensity-score analysis. Eur J Gastroenterol Hepatol 2021;33:1110-6. [PMID: 33741800 DOI: 10.1097/MEG.0000000000002133] [Reference Citation Analysis]
179 Lv Y, Bai W, Li K, Wang Z, Guo W, Luo B, Wang J, Wang Q, Wang E, Xia D, Li X, Yuan J, Han N, Niu J, Yin Z, Fan D, Han G. Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study. Am J Gastroenterol 2021;116:1447-64. [PMID: 33630766 DOI: 10.14309/ajg.0000000000001194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
180 van Straten G, van Dalen D, Mesu SJ, Rothuizen J, Teske E, Spee B, Favier RP, van Geijlswijk IM. Efficacy of orally administered sodium benzoate and sodium phenylbutyrate in dogs with congenital portosystemic shunts. J Vet Intern Med 2019;33:1331-5. [PMID: 30916412 DOI: 10.1111/jvim.15477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
181 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Reference Citation Analysis]
182 Lee JG, Sohn JH, Jeong JY, Kim TY, Kim SM, Cho YS, Kim Y. Combined effect of hepatic venous pressure gradient and liver stiffness on long-term mortality in patients with cirrhosis. Korean J Intern Med 2020;35:88-98. [PMID: 30791681 DOI: 10.3904/kjim.2018.151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]